These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8629663)

  • 1. Therapeutic options in patients with hormone-refractory prostate cancer.
    Anand N
    Am J Med; 1996 Feb; 100(2):243-4. PubMed ID: 8629663
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxyflutamide may not always be a pure antiandrogen.
    Yeh S; Miyamoto H; Chang C
    Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
    [No Abstract]   [Full Text] [Related]  

  • 3. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Walsh PC
    J Urol; 1996 May; 155(5):1705. PubMed ID: 8627865
    [No Abstract]   [Full Text] [Related]  

  • 4. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Small EJ
    J Urol; 1996 May; 155(5):1704-5. PubMed ID: 8627864
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
    Figg WD; Sartor O; Cooper MR; Thibault A; Bergan RC; Dawson N; Reed E; Myers CE
    Am J Med; 1995 Apr; 98(4):412-4. PubMed ID: 7535978
    [No Abstract]   [Full Text] [Related]  

  • 8. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
    Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
    Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of mutant androgen receptors by flutamide.
    Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casodex: preclinical studies and controversies.
    Furr BJ
    Ann N Y Acad Sci; 1995 Jun; 761():79-96. PubMed ID: 7625752
    [No Abstract]   [Full Text] [Related]  

  • 13. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 17. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
    Fujikawa K; Matsui Y; Fukuzawa S; Takeuchi H
    Eur Urol; 2000 Feb; 37(2):218-22. PubMed ID: 10705202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.